Abstract #2786

31P and 1H MRS of Androgen-Independent and Androgen-Dependent Prostate Cancer Xenografts: Lonidamine Selectively Decreases Tumor Intracellular pH, Bioenergetics and Increases Lactate

Kavindra Nath¹, David Nelson¹, Dennis Leeper², and Jerry Glickson¹

¹University of Pennsylvania, Philadelphia, PA, United States, ²Thomas Jefferson University, Philadelphia, PA, United States

Lonidamine (LND) effects were measured in vivo by ³¹P and ¹H MRS in androgen-independent (PC3) and androgen-dependent (LNCaP) prostate cancer xenografts indicating a sustained and tumor-selective decrease in intracellular pH (pHi) and extracellular pH (pHe), and decrease in tumor bioenergetics (βNTP/Pi) by 75.0 % and 79.0 % in PC3 and LNCaP, respectively, relative to the baseline levels. Steady-state levels of tumor lactate were significantly increased ~ 2 fold at 60 min. post-LND. The decline of pHi, pHe, bioenergetics and increase in lactate produced increased therapeutic efficacy when LND was combined with other therapeutic interventions (chemotherapy, radiation, and hyperthermia).

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.